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exclusion criteria. The combined odds ratio was 1.72 (95% CI: 1.432 to 2.070), indicating 
the odds of fetal malformation is higher among women taking antidepressants than 
those not receiving SSRIs. In the pairwise analysis, 2 of the 14 pairwise comparisons 
were statistically significant: fluoxetine compared to control (OR 1.774, 95% CI 1.008 
to 2.925); paroxetine compared to control (OR 1.752, 95% CI 1.057 to 2.953). The result-
ing pairwise odds ratios suggested a lowest odds of malformation to highest odds 
was citalopram, sertraline, paroxetine, fluoxetine. ConClusions: The risk of mal-
formation is an important consideration when treating pregnant women. This study 
suggests that there is an increase in the odds of fetal malformation when exposed 
to SSRIs in utero during the period of organogenesis. The risk appears to be highest 
with fluoxetine and paroxetine, and lower for citalopram.
Mental HealtH – Cost Studies
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objeCtives: The costs of schizophrenia in Austria are high and new long acting 
injectable (LAI) antipsychotics might be able to reduce costs due to a reduction 
of hospital stays. We aim to estimate budget effects of the introduction of a new 
LAI (Paliperidone Palmitate) in Austria. Methods: A budget impact analysis was 
conducted that took direct costs of illness into account (i.e. costs for inpatient 
and outpatient services and drug costs). We used official Austrian remuneration 
prices as input parameters. The robustness of the model was checked by means 
of deterministic sensitivity analyses with regard to switch rates to Paliperidone 
Palmitate and rehospitalisation rates. Results: According to our calculations, 
direct total costs of schizophrenia in Austria reach € 254.36 million a year. The 
drug costs are € 26.14 million and the costs for inpatient and outpatient services 
are € 228.22 million. Within the next five years, drug costs will slightly decrease to 
€ 25.77 million due to a bigger market share of generic Quetiapine which offsets 
the higher drug costs of Paliperidon palmitate. The use of Quetiapine is associ-
ated with a higher rate of rehospitalisation. Therefore, costs for inpatient and 
outpatient services will increase to € 228.65 million, which results in an overall 
effect of € 60,000 additional costs compared to the situation without paliperidone 
palmitate. ConClusions: The introduction of a new treatment of schizophrenia 
in Austria is budget neutral.
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objeCtives: Depression is associated with reduced cognitive function and signifi-
cant health care costs; however, the extent to which these two are related remains 
unclear. This study compared follow-up health care costs for major depressive dis-
order patients with and without cognitive dysfunction after antidepressant (AD) 
initiation. Methods: A large US health plan affiliated with OptumInsight was used 
to identify depressed patients with a newly prescribed AD who could be surveyed 
to assess cognitive function. Patients with neurological diseases associated with 
cognitive dysfunction were excluded. Patients were mailed a survey invitation and 
consent form. Patients maintained eligibility by confirming a depressive diagno-
sis and no excluding diagnoses. Consenting, eligible patients were interviewed by 
telephone and completed 4 cognitive function tests. Patients were classified as 
“cognitive normal (CN)” or “cognitive dysfunction (CD)” based on test scores relative 
to normative data. All-cause health care costs in the 3 months post-AD initiation 
were calculated from pharmacy and medical claims. T-tests compared 3-month 
costs of CN versus CD. Gamma models with log link compared health care costs 
between CD and CN patients, adjusting for race, sex, age, education, employment, 
depression severity, and comorbidities. Results: A total of 13,537 patients were 
invited to participate in the study and 564 patients maintained eligibility and com-
pleted the study. Patients were mostly female (80%), mean age was 41 years, 98% 
had a high school degree or higher, and 84% were employed. A total of 45% (n= 255) 
met criteria for CD. Mean health care costs were $4,996 for all patients. Costs were 
$6,457 for the CD group compared to $3,787 for the CN (p = 0.038). In the gamma 
models with costs as the outcome, CD patients had costs 1.43 times higher than CN 
patients (95% CI: 1.13, 1.81). ConClusions: In this study population, health care 
costs were significantly higher in patients with cognitive dysfunction compared to 
those without cognitive dysfunction.
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objeCtives: To assess the economic burden and health care utilizations of 
patients diagnosed with post-traumatic stress disorder (PTSD) in the U.S. veteran 
population. Methods: Patients diagnosed with PTSD were identified (International 
Classification of Disease 9th Revision Clinical Modification [ICD-9-CM] diagnosis 
code 309.81) from the Veterans Health Administration (VHA) dataset from October 
01, 2009 through September 30, 2011. The first diagnosis date was designated as the 
index date. A comparator group was created by identifying patients without PTSD 
but with the same age, region, gender and index year, and who were matched by 
baseline Charlson Comorbidity Index. A randomly chosen index date served to 
severity of depression on these outcomes. These preliminary results need to be 
confirmed on the full dataset.
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objeCtives: To identify factors associated with early response at 4 weeks of treat-
ment with olanzapine and to assess whether early response is associated with 
better longer-term outcomes for patients with schizophrenia in China. Methods: 
A post-hoc analysis was conducted using data from the Chinese schizophrenia 
subgroup (n= 330) of a multicountry, 6-month, prospective, observational study of 
outpatients with schizophrenia/bipolar mania who were initiated or switched to oral 
olanzapine. Stepwise logistic regression controlling for baseline clinical character-
istics, participation in weight education program at baseline, and compliance with 
antipsychotics over first 4 weeks of olanzapine treatment was used to identify fac-
tors associated with early response. Mixed Models Repeated Measures with baseline 
covariates were used to compare outcomes over time between early responders and 
early non-responders to olanzapine. Results: A total of 130 patients (40%) achieved 
early response. The models revealed that significant factors associated with a higher 
likelihood of achieving early response were higher CGI-Sevirity score (OR= 1.51, 95% 
CI: 1.15-1.97), fewer years since first diagnosis (OR= 0.94, 95% CI: 0.90-0.98), a greater 
number of social interactions (OR= 1.22, 95% CI: 1.05-1.40), participation in a weight 
education program (OR= 1.81, 95% CI: 1.04-3.15) at study entry, and high medication 
compliance with antipsychotics during the first 4 weeks of treatment (OR= 2.98, 95% 
CI: 1.59-5.58). When compared to early non-responders, early responders achieved a 
significantly higher endpoint response and significantly greater symptom improve-
ment at end point (CGI-Severity) and a greater improvement in level of functional 
outcomes (all p< 0.05). ConClusions: High levels of compliance to prescribed 
antipsychotic and participation in a weight education program were associated with 
early response in schizophrenia patients in China. Early response was associated 
with greater improvement in symptomatic, functional and quality-of-life outcomes 
at 6 months compared to early non-response. Current findings are consistent with 
previous research outside of China.
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objeCtives: Patients with major depressive disorder (MDD) frequently suffer from 
concomitant pain symptoms, which are associated with higher depression sever-
ity and worse quality of life. We describe the baseline factors associated with pain 
persistence in patients with MDD during a 3-month follow-up period. Methods: 
Patients from Asia (n= 909) presenting with a new or first episode of MDD were 
enrolled in a 3-month prospective observational study. This report analyzes the 
709 (78%) patients assessed at baseline and 3 months. Demographics, depressive 
symptoms (Hamilton Depression Scale), overall severity (Clinical Global Impression 
Severity score), somatic symptoms (Somatic Symptom Inventory) and quality of 
life (Euro QOL -5D) were assessed. Logistic regression models were fitted to assess 
the relationship between baseline factors and pain persistence during follow-
up. Results: Of the 709 patients analyzed , 349 (49%) had pain at baseline. Forty 
three per cent of the patients (151) having pain at baseline still presented with pain 
at 3-months. Patients with persistent pain had more frequently suffered from previ-
ous MDD episodes (54% vs 39%) , were less likely to be older than 60 (11 vs. 21%), and 
had a higher number of medical comorbid conditions (14% vs 5% with two or more 
co-morbidities). The logistic model adjusting for other baseline covariates confirmed 
these results. ConClusions: A high proportion of patients with depression who 
presented with pain at baseline still suffered from pain symptoms at 3 months. A 
history of depression and the presence of other medical conditions were risk factors 
for pain persistence at 3-months.
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objeCtives: Assessing the safety of selective serotonin reuptake inhibitor (SSRI) 
use during pregnancy is complicated, especially given the array of treatment option. 
The objective of this study was to evaluate the risks of fetal malformation of SSRI 
use during pregnancy. Methods: A search for prospective studies evaluating fetal 
malformation with maternal use of citalopram, fluoxetine, paroxetine, or sertraline 
was conducted using the databases of MEDLINE, PsycINFO and EMBASE for the period 
of 1974 to March 21, 2013. The key terms used were: ‘serotonin reuptake inhibitors’, 
‘pregnancy’, ‘prospective studies’. The inclusion criteria in addition to prospective 
studies included: 1) malformation outcome; 2) citalopram, fluoxetine, paroxetine, 
and/or sertraline; 3) drug exposure in first trimester; and 4) compared to control 
group of either ‘no SSRI exposure’ or ‘nonteratogenic agents’. The exclusion criteria 
included: 1) evaluation of SSRI as a drug class, and 2) venlafaxine or bupropion. A 
Bayesian random-effects indirect treatment comparison model was used to perform 
the analysis. Results: The search resulted in 64 articles. Eight articles met inclusion/
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objeCtives: To estimate the direct total and component medical costs for inpatient 
and outpatient care for patients with schizophrenia in Tianjin, China. Methods: 
Data were extracted from the Tianjin Urban Employee Basic Medical Insurance data-
base. Patients (N= 2125) who were aged ≥ 18 years, at least 1 diagnosis of schizophre-
nia and 12-month continuous enrollment after their first observed schizophrenia 
diagnosis between 2008 and 2010 were included. Psychiatric-related inpatient and 
outpatient direct medical costs were estimated. Results: During the study period, 
60.8% of patients had at least one inpatient admission and 39.2% used only outpa-
tient services. The mean (± SD) total annual cost for inpatients was $2771.9±2175.6, 
with 88.9% ($2465.4±2022.5) due to non-drug medical costs and 11.1% ($306.6±461.7) 
for medications. Total annual costs for the outpatient only group were $230.6±487.3 
with 4.4% ($10.1±40.8) for non-drug medical costs and 95.6% ($220.5±470.3) for medi-
cations. Antipsychotics accounted for 50.4% of the total annual medication costs 
in the inpatient group and 60.0% in outpatient only group. On average, inpatients 
had 2.2 psychiatric hospitalizations and 2.2 outpatient visits. Outpatient only group 
had 5.9 outpatient visits. The highest costs per psychiatric-related inpatient admis-
sion were general care and non-drug treatment (49.8%), followed by examinations 
(21.6%), bed fee (14.6%), and medications (7.8%). The majority of costs for outpatient 
visits were due to medications (96.2%). ConClusions: Patients who were hospital-
ized for schizophrenia incurred considerably more costs than those who were only 
treated at outpatient setting in Tianjin China, primarily driven by non-drug medical 
care. This suggests that the use of more effective treatments to minimize the risk 
of hospitalization could lead to reduced total health care costs.
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objeCtives: To estimate the health care resource utilization and direct medi-
cal costs of patients with schizophrenia in Tianjin, China. Methods: Data were 
obtained from the Tianjin Urban Employee Basic Medical Insurance database. Adult 
patients with ≥ 1 diagnosis of schizophrenia and 12-month continuous enroll-
ment after the first observed schizophrenia diagnosis between 2008 and 2010 were 
included. Both all-cause and psychiatric-related resource utilization and direct 
medical costs were estimated. Two-sample t-test was used to assess cost differ-
ence. A multiple linear regression model was applied to identify factors associated 
with total cost. Results: A total of 2125 patients were included, with mean age 
of 52.3 years, 49.3% male and 55.7% retired. 60.8% of the patients experienced ≥ 1 
psychiatric-related hospitalizations during the study period. Median (min-max) 
length of stay was 88 (1-365) days per admission and 91 (1-365) days per patient-
year. 58.9% of the patients experienced ≥ 1 psychiatric related outpatient visits. 
Median number of outpatient visits was 4 (1-82). Mean (±SD) total all-cause and 
psychiatric-related direct medical costs were $2863.5±2638.4 and $1774.5±2123.3 
per patient-year respectively, with significant difference between hospitalized and 
non-hospitalized patients ($3953.0 vs. $1176.9, p< 0.001; $2771.9 vs. $230.6, p< 0.001). 
The regression model revealed that patients with more hospitalizations/outpatient 
visits and non-retired patients were more likely to incur higher psychiatric-related 
annual costs. ConClusions: Costs related to treatment with schizophrenia was 
considerable in Tianjin China, driven mainly by psychiatric hospitalizations. Patients 
with psychiatric-related hospitalizations used more medical resources and had 
higher direct medical cost than patients who were not hospitalized.
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objeCtives: The economic burden of Alzheimer disease goes beyond the direct 
health cost as the disease has significant economic and social impact on both 
patients themselves and their families (carers). Despite the fact that Greece is 
plagued by the economic crisis, with major cuts in health expenditure, very little 
is known about the cost of chronic diseases and the most cost-effective ways to 
manage them. The study’s’ aim is to estimate, for the first time in Greece, the cost of 
Alzheimer’s disease, per each severity stage, evaluating apart from the direct costs 
of disease, the cost of carers. Methods: The pilot sample was 46 patients from 
two Alzheimer centers. A cost analysis was conducted from the socio-economic 
perspective. Data regarding the carers’ time were collected via a questionnaire 
developed by the researchers of this study and was partly based on the research 
tool CATS (Caregiver Activities Time Survey) as it was adopted by Jacobsen et al. 
(2011). Results: The total annual cost of the disease was estimated at € 12,140 (SD: 
6,555.9) for the mild stage (MMSE* 30-21), at € 13,735 (SD: 7,858.7) for the moderate 
stage (MMSE 20-11), and € 22,666 (SD: 8,467.2) for the severe stage (MMSE 10-0) (for 
outpatient cases), 87% higher compared to the mild stage of disease. On average, 
from the total cost of disease, 77% was the cost of the primary and the second-
ary caregiver, 8.7% is the cost of medication and 5% is the hospitalization cost. 
Productivity loss of the primary caregiver exceeds 5% of the total cost per patient in 
mild stage. ConClusions: As the patient gets worse and goes from mild to more 
severe stages, the total health care cost increase. It is important, when possible, to 
prolong the stay of patients in the early stages of the disease.
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SCHIzoPHrenIa and negatIve SyMPtoMS – Burden of tHe dISeaSe In 
Seven Central and eaStern euroPean (Cee) CountrIeS: tHe reSultS of 
tHe lIterature revIew
Walczak J.1, Augustyńska J.1, Miernik K.1, Stelmachowski J.1, Pieniazek I.1, Obrzut G.1, 
minimize selection bias. Patients in both groups were required to be at least 18 years 
old, and have continuous medical and pharmacy benefits 1 year pre- and 1 year 
post-index date. One-to-one propensity score matching was applied to compare 
follow-up health care costs and utilizations between patients with and without 
PTSD. Results: A total of 938,138 patients were identified for the PTSD and com-
parison cohorts. After 1:1 matching, a total of 333,303 of patients were matched from 
each group, and baseline characteristics were balanced. Patients diagnosed with 
PTSD used more health care resources for inpatient (8.57% vs. 2.58%, p< 0.01), emer-
gency room (13.45% vs. 7.15%, p< 0.01), physician office (99.59% vs. 55.67%, p< 0.01), 
outpatient (99.64% vs. 56.46%, p< 0.01), and pharmacy visits (89.97% vs. 56.47%, 
p< 0.01) than patients in the comparator cohort. The PTSD cohort also incurred 
higher health care costs for inpatient ($2,587 vs. $719, p< 0.01), emergency room 
($133 vs. $66, p< 0.01), physician office ($3,404 vs. $1,254, p< 0.01), outpatient ($3,735 
vs. $1,430) and pharmacy visits ($629 vs. $362, p< 0.01). ConClusions: Study results 
suggest that the economic burden and health care utilizations were significantly 
higher for patients with PTSD versus those without.
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PatIentS wItH anxIety verSuS tHoSe wItHout
Xie L.1, Wang L.2, Du J.1, Li L.2, Baser O.3
1STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research, Dallas, TX, USA, 
3STATinMED Research/The University of Michigan, Ann Arbor, MI, USA
objeCtives: To compare health care costs and utilizations between patients with 
anxiety versus those without in the U.S. veteran population. Methods: A retro-
spective database analysis was performed using the Veterans Health Administration 
(VHA) Medical SAS datasets (01OCT2008-30SEP2012). Patients diagnosed with anxi-
ety were identified (ICD-9-CM: 300.xx) from October 01, 2009 through September 30, 
2011. The first diagnosis date was designated as the index date for the anxiety group. 
A group of non-anxiety patients of the same age, region, gender and index year 
were identified and matched by baseline Charlson Comorbidity Index (CCI) as the 
comparison group. The index date for the comparator group was randomly chosen 
to reduce the selection bias. Patients in both groups were required to be at least 18 
years old, and have continuous medical and pharmacy benefits 1 year before and 
1 year after the index date. One-to-one propensity score matching was applied to 
compare the health care costs and utilizations during the follow-up period between 
the anxiety and comparison groups, adjusted for baseline demographic and clinical 
characteristics. Results: A total of 928,724 patients were identified for the anxiety 
and comparison cohorts. After 1:1 matching, 338,373 of patients were matched from 
each group and the baseline characteristics were well-balanced. Patients with anxi-
ety had higher percentages of inpatient (11.03% vs. 2.74%, p< 0.01), emergency room 
(18.64% vs. 7.50%, p< 0.01), physician office (99.53% vs. 59.16%, p< 0.01), outpatient 
(99.68% vs. 59.91, p< 0.01) and pharmacy visits (91.42% vs. 59.13%, p< 0.01). The anxi-
ety group had higher expenditures in inpatient ($3,347 vs. $782, p< 0.01), emergency 
room ($204 vs. $68, p< 0.01), physician office ($3,527 vs. $1,435, p< 0.01), outpatient 
($3,948 vs. $1,621) and pharmacy visits ($745 vs. $429, p< 0.01) than the comparison 
group. ConClusions: Results suggest that patients diagnosed with anxiety used 
significantly more health care resources and incurred significantly higher health 
care costs compared to patients without.
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objeCtives: Increasing prevalence of dementia highlights the need for a better 
understanding of the cost burden for health policy makers. By descriptive analysis 
of specific cost impacts, cost-of-illness (COI) studies are an essential instrument 
for decision making and planning of health care services. Therefore the purpose of 
this study was to review COI studies of dementia in order to analyze cost compo-
nents and underlying methods in an international context. Methods: A system-
atic review according to the PRISMA-guidelines was conducted from 2002-2012 in 
order to identify COI studies related to dementia, searching the PubMed, Cochrane, 
EMBASE and NHS Economics Evaluations databases. Annual outcomes per patients 
were analyzed for total, direct, indirect and informal costs. Results: In total 25 
studies were evaluated. Total costs showed an annual range from USD 3.512 to USD 
59.526 in 14 health care systems. This is due to the fact, that the composition of cost 
components and corresponding methods indicated a large heterogeneity in terms 
of both – study characteristics (e.g. diagnosis, care setting, disease stratification) 
and composition of cost components. The majority of studies (92%, n= 23) included 
direct costs, however different cost components and underlying measurements 
were applied. Almost two thirds (60%, n= 15) of the studies included informal costs, 
whereas 9 used the replacement cost approach and 6 studies the opportunity cost 
approach. ConClusions: Outcomes of COI studies in dementia indicate a large 
range, due to differences in health care systems, but also because of methodo-
logical approaches and cost components included. Dementia as a long-lasting and 
progressive disease affects multiple cost dimensions and thereby poses a complex 
challenge for policy makers. In addition, international guidelines on cost analysis 
of dementia are lacking. Standards regarding the methodology of COI studies in 
dementia by the scientific community would be useful. Funded by the European 
Commission, ICT-FP7, project-ID-287509.
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